Scholars@Duke
Herbert Pang

Herbert Pang

Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
herbert.pang@duke.edu
Duke Box 2721, Durham, NC 27710
2424 Erwin Road Ste 1102, 11107 Hock Plaza, Durham, NC 27705

Featured Works

Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.

Journal article Genet Epidemiol · April 2013 Featured Publication A variety of prediction methods are used to relate high-dimensional genome data with a clinical outcome using a prediction model. Once a prediction model is developed from a data set, it should be validated using a resampling method or an independent data ... Full text Link to item Cite

Determinants of a subject's decision to participate in clinical anesthesia research.

Journal article Anesth Analg · February 2013 Featured Publication BACKGROUND: A top priority for research studies is to ensure that potential participants receive adequate information to make a truly informed decision. Understanding patient experiences with the recruitment process may identify areas for improvement in th ... Full text Link to item Cite

Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.

Journal article J Thorac Oncol · January 2013 Featured Publication INTRODUCTION: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS: Patients with untreated, measurable, limited-stage small-c ... Full text Link to item Cite

NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.

Journal article Gut · September 2012 Featured Publication OBJECTIVE: Immune responses are important in dictating non-alcoholic steatohepatitis (NASH) outcome. We previously reported that upregulation of hedgehog (Hh) and osteopontin (OPN) occurs in NASH, that Hh-regulated accumulation of natural killer T (NKT) ce ... Full text Link to item Cite

Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes.

Journal article Stat Med · July 10, 2012 Featured Publication Many statistical methods for microarray data analysis consider one gene at a time, and they may miss subtle changes at the single gene level. This limitation may be overcome by considering a set of genes simultaneously where the gene sets are derived from ... Full text Link to item Cite

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.

Journal article J Thorac Oncol · April 2012 Featured Publication INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 m ... Full text Link to item Cite

Gene selection using iterative feature elimination random forests for survival outcomes.

Journal article IEEE/ACM Trans Comput Biol Bioinform · 2012 Featured Publication Although many feature selection methods for classification have been developed, there is a need to identify genes in high-dimensional data with censored survival outcomes. Traditional methods for gene selection in classification problems have several drawb ... Full text Open Access Link to item Cite

Relationship type, condom use and HIV/AIDS risks among men who have sex with men in six Chinese cities.

Journal article AIDS Care · 2012 Featured Publication This study is the first to examine the role of partner type in sexual practices of men who have sex with men (MSM) in China. Using cross-sectional self-administered questionnaires (N=692) with MSM in six Chinese cities (Shanghai, Guangzhou, Shenzhen, Xi'an ... Full text Link to item Cite

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

Journal article J Clin Oncol · November 20, 2011 Featured Publication PURPOSE: The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS AND METHODS: Patients with ES-SCLC received cisplatin 30 mg/m(2) and irinotecan 65 mg/m(2) on days 1 a ... Full text Link to item Cite

A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.

Journal article Clin Colorectal Cancer · September 2011 Featured Publication BACKGROUND: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. PATIENTS AND METHODS: Nineteen patients wi ... Full text Link to item Cite

Pathway-based identification of SNPs predictive of survival.

Journal article Eur J Hum Genet · June 2011 Featured Publication In recent years, several association analysis methods for case-control studies have been developed. However, as we turn towards the identification of single nucleotide polymorphisms (SNPs) for prognosis, there is a need to develop methods for the identific ... Full text Link to item Cite

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

Journal article Oncologist · 2011 Featured Publication PURPOSE: For patients with metastatic colorectal cancer (mCRC), no standard therapy exists after progression on 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab. Preclinical data demonstrated that combined vascular endothe ... Full text Link to item Cite

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

Journal article Anticancer Res · January 2011 Featured Publication AIM: This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer. PATIENTS AND METHODS: Patients with previously untreate ... Link to item Cite

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Journal article J Thorac Oncol · October 2010 Featured Publication HYPOTHESIS: Malignant mesotheliomas (MMs) express vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and cKIT. Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT. We evaluat ... Full text Link to item Cite

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

Journal article J Thorac Oncol · October 2010 Featured Publication INTRODUCTION: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the p ... Full text Link to item Cite

Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis.

Journal article Hum Genomics · October 2010 Featured Publication Breast cancer tumours among African Americans are usually more aggressive than those found in Caucasian populations. African-American patients with breast cancer also have higher mortality rates than Caucasian women. A better understanding of the disease a ... Full text Link to item Cite

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Journal article J Thorac Oncol · March 2010 Featured Publication INTRODUCTION: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was t ... Full text Link to item Cite

Pathway analysis using random forests with bivariate node-split for survival outcomes.

Journal article Bioinformatics · January 15, 2010 Featured Publication MOTIVATION: There is great interest in pathway-based methods for genomics data analysis in the research community. Although machine learning methods, such as random forests, have been developed to correlate survival outcomes with a set of genes, no study h ... Full text Link to item Cite

Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data.

Journal article Biometrics · December 2009 Featured Publication High-dimensional data such as microarrays have brought us new statistical challenges. For example, using a large number of genes to classify samples based on a small number of microarrays remains a difficult problem. Diagonal discriminant analysis, support ... Full text Link to item Cite

Building pathway clusters from Random Forests classification using class votes.

Journal article BMC Bioinformatics · February 6, 2008 Featured Publication BACKGROUND: Recent years have seen the development of various pathway-based methods for the analysis of microarray gene expression data. These approaches have the potential to bring biological insights into microarray studies. A variety of methods have bee ... Full text Link to item Cite

Pathway analysis using random forests classification and regression.

Journal article Bioinformatics · August 15, 2006 Featured Publication MOTIVATION: Although numerous methods have been developed to better capture biological information from microarray data, commonly used single gene-based methods neglect interactions among genes and leave room for other novel approaches. For example, most c ... Full text Link to item Cite